InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

CG Oncology, Inc.

CGON Clue Score59
United States Fiscal year ends December CIK 0001991792
$63.82 +0.89% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $63.82 +43.54% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 25 Jan 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue0.2Operating income−55.4Net income−48.6EPS, diluted−15.65Fiscal year 2024Revenue1.1 +458.3%Operating income−114.7Net income−88.0EPS, diluted−1.41Fiscal year 2025Revenue4.0 +254.7%Operating income−190.8Net income−161.0EPS, diluted−2.08
FY2023FY2024FY2025
Revenue 0.2 1.1 4.0
Growth +458.3% +254.7%
Operating income −55.4 −114.7 −190.8
Net income −48.6 −88.0 −161.0
Growth
EPS, diluted −15.65 −1.41 −2.08

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2023Operating margin−27,180.9%Net margin−23,827.0%Fiscal year 2024Operating margin−10,067.3%Net margin−7,729.5%Free cash flow margin−6,931.3%Fiscal year 2025Operating margin−4,722.1%Net margin−3,985.0%Free cash flow margin−3,279.2%
FY2023FY2024FY2025
Operating margin −27,180.9% −10,067.3% −4,722.1%
Net margin −23,827.0% −7,729.5% −3,985.0%
Free cash flow margin n/a −6,931.3% −3,279.2%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−45.7Fiscal year 2024Operating cash flow−78.7Capital expenditure−0.2Free cash flow−78.9Fiscal year 2025Operating cash flow−132.3Capital expenditure−0.1Free cash flow−132.5
FY2023FY2024FY2025
Operating cash flow −45.7 −78.7 −132.3
Capital expenditure n/a −0.2 −0.1
Free cash flow n/a −78.9 −132.5
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2023Cash8.3Shareholders’ equity−123.1Fiscal year 2024Cash257.1Total debt0.0Net cash (debt)257.1Shareholders’ equity733.4Debt to equity0.00Fiscal year 2025Cash32.5Total debt3.0Net cash (debt)29.5Shareholders’ equity752.6Debt to equity0.00
FY2023FY2024FY2025
Cash 8.3 257.1 32.5
Total debt n/a 0.0 3.0
Net cash (debt) n/a 257.1 29.5
Shareholders’ equity −123.1 733.4 752.6
Debt to equity n/a 0.00 0.00

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
−27,180.9% −10,067.3% −4,722.1%
−23,827.0% −7,729.5% −3,985.0%
n/a −6,931.3% −3,279.2%
Spending
22,427.5% 7,208.3% 2,887.2%
4,853.4% 2,959.0% 1,820.0%
n/a 20.5% 3.3%
Returns
n/a −12.0% −21.4%
−24.4% −11.7% −20.3%
Balance and payout
n/a 0.00 0.00
7.3% 2.8% 4.9%